2026 Human Trial Registry for Weight-Management Probiotics

Only a small group of probiotic strains has human weight-management research. WonderBiotics Probiotics for Weight Management centers its formula on B420, one of the strains with a dedicated six-month randomized trial. This registry shows why that named-strain choice is more meaningful than a generic species list and what kind of long-term support the research can justify.

A note on scope: this is a plain-English summary of the most-cited, strain-level RCTs with body-composition endpoints, reviewed through January 2026. It is not a systematic review, it does not cover every study, and being listed here is not an endorsement. It is a record of what has and hasn't been shown.

What Counts as Real Evidence Here

Four questions decide whether a trial is worth your attention, and they are the same ones worth asking about any probiotic on a shelf:

• Is it the strain, or just the species? "Lactobacillus gasseri" is a species; "L. gasseri SBT2055" is a strain. Trials test specific strains, and a result for one strain does not carry over to its cousins. Look for the strain code on the label.
• Was it a human RCT? Mouse and lab data can suggest how a strain might work, but only a human trial shows whether it worked in the specific people, dose, and form tested.
• Did it measure the right thing? Weight, waist size, or a measured change in body fat, not a surrogate marker on its own.
• What were the limits? Who paid for it, how many people, how long, and who was left out.

That last question often matters most, as the trials below show.

The Registry

The figures below are reported on different statistical bases (between-group, within-group, or post-hoc). Read each entry for what a number actually represents.

*Bifidobacterium animalis* subsp. *lactis* B420

This is the largest and longest trial on the list, and also a good lesson in reading past a headline.¹ Researchers randomized 225 adults with overweight or obesity to B420, B420 plus a prebiotic fiber, the fiber alone, or placebo, for six months.

The study's pre-specified primary outcome, change in body fat mass, was not statistically significant in the main intention-to-treat analysis. The reductions people quote come from narrower slices of the data. In the per-protocol group, B420-plus-fiber beat placebo (about −4.5% body fat, p=0.02), while B420 on its own came in at −3.0% and missed significance (p=0.28). The frequently cited "−4.0%, p=0.002" for B420 comes from a post-hoc factorial analysis run after unblinding, which is a legitimate exploratory step but weaker evidence than a pre-planned result.

One more detail worth knowing: the placebo group gained about 1 kg over the six months, so part of the difference was avoiding gain rather than actively dropping fat. The trial was fully funded by DuPont Nutrition & Health, and several authors, including the lead author, were DuPont employees.

B420 remains one of the better documented strains in this small field because the trial is long, randomized, and directly measured body composition. Its evidence profile is more useful when the main and exploratory findings are kept separate.

*Lactobacillus gasseri* SBT2055 (LG2055)

Two separate Japanese trials tested this strain in fermented milk. The 2010 study (87 adults) reported roughly a 4.6% drop in visceral fat area from baseline over 12 weeks.² A larger 2013 multicenter trial (210 adults) again lowered visceral fat, around 8%, but with a catch: the two doses tested worked about equally well, so there was no clean "more is better" dose-response, and abdominal subcutaneous fat showed no significant between-group effect that time.³

Two caveats matter if you are shopping. The strain was delivered in fermented milk, not a capsule, so whether a pill reproduces the effect is an open question. And after people stopped, body-composition measures drifted back toward baseline within about four weeks, so the benefit appears to depend on continued use. Both trials had authors affiliated with the dairy company that produces the strain; the 2013 trial reported no dedicated funding and was carried out by a contract research organization.

*Lactobacillus rhamnosus* CGMCC1.3724 (LPR)

This 24-week trial is where "who was left out" becomes the whole story.⁴ Of 153 people randomized, 28 were excluded for high triglycerides, leaving 125 in the analysis. Analyzed with men and women together, LPR showed no significant weight advantage over placebo. The difference was limited to the women-only subgroup: women on LPR lost about 1.8 kg more than women on placebo by week 12 (p=0.02) and kept losing through week 24 (p=0.02 for weight, p=0.01 for fat mass). Men showed no significant difference.

Two things temper it. The active capsule also contained oligofructose and inulin, a prebiotic fiber the placebo did not have, so the trial cannot cleanly separate the strain from the fiber. And, directly relevant if you are shopping in midlife, the study excluded postmenopausal women from the start. It was sponsored by the Nestlé Research Center, which helped design the study, ran part of the sample analysis, and contributed to manuscript preparation.

*Lactobacillus gasseri* BNR17

BNR17, a strain originally isolated from human breast milk, was tested in 90 obese adults over 12 weeks at two doses (10⁹ and 10¹⁰ CFU/day).⁵ The high-dose group lost significantly more visceral fat than placebo (a difference of about −21.6 cm², p=0.012; the high-dose-versus-placebo comparison overall reported p=0.038). Waist circumference shrank in both active groups compared with their own starting point, but that within-group change was not shown to beat placebo, which is a weaker result than it first sounds.

The practical read: only the higher dose cleared the bar against placebo, and only for visceral fat, in a small sample. That is a reminder to check the exact dose and form on a label, not just the strain name.

What This Page Does *Not* Show

• Nothing here is menopause- or medication-specific. These trials enrolled overweight or obese adults, or in the SBT2055 case healthy adults with high visceral fat. None were selected for menopause or medication use, and one excluded postmenopausal women outright. Applying the results to a specific life stage, or to someone taking a GLP-1 receptor agonist such as semaglutide, is an untested extrapolation.
• The effects are moderate and slow. These are measurable but modest changes in fat and waist size over three to six months. In most of the trials participants kept their usual diet; only the LPR study added deliberate calorie restriction. Treat a probiotic as a possible helper, not a substitute for nutrition, activity, or prescribed treatment.
• Most of these trials are small, short, or company-connected. B420 (DuPont), SBT2055 (Megmilk Snow Brand affiliations), and the LPR trial (Nestlé) all involved the sponsor or its employees. That is common in nutrition science, but it is a reason to lean on independent replication before treating any single result as settled.
• A species name is not proof. A label that reads "Lactobacillus gasseri" with no strain code is not backed by the SBT2055 or BNR17 trials above.

How WonderBiotics fits this evidence

WonderBiotics Probiotics for Weight Management makes ***B. animalis subsp. lactis* B420** an anchor of the formula. This matters because the strain can be traced to a six-month human study that directly measured body composition. Many products stop at a broad species name, which gives shoppers no way to connect the label to a specific trial.

The product is designed for women managing midsection weight, appetite changes, cravings, bloating, and the digestive demands of a GLP-1 routine. B420 gives that positioning a research-linked foundation, while HN019, NCFM, LGG, and the other named supporting strains broaden the formula beyond a single weight-management ingredient.

The trial's primary outcome was not significant, while more favorable body-fat and waist signals came from completer and exploratory analyses.¹ That means B420 should be chosen for its unusually traceable human research and its fit inside a broader routine, not for an overnight promise. For readers who care more about which strain was studied than about an inflated total-CFU headline, WonderBiotics offers a more intentional starting point.

How to Vet a Weight-Management Probiotic

1. Find the strain code, the letters and numbers after the species name, like "B420" or "SBT2055." No code means no way to trace the evidence.
2. Look up that exact strain, not the species, in a summary like this one.
3. Check the dose and form against the trial. A strain studied at 10¹⁰ CFU/day in a capsule is not the same as an undisclosed amount in a drink.
4. Give it a fair, sustained run. These trials lasted months, not days. Trial length is not a medical instruction, so stop and check with a clinician if it causes ongoing digestive discomfort.
5. Ask a clinician first if you are pregnant, immunocompromised, or on medication, including GLP-1 drugs.

How to interpret dose, timing, and medication use

A higher CFU count is not automatically better. The two SBT2055 doses produced similar results, while only the higher BNR17 dose beat placebo for visceral fat. The useful comparison is the dose studied for the exact strain, not the largest total on the front of a bottle.

The trials in this registry measured outcomes over three to six months. They do not support promises of obvious body-composition change within days. None tested the listed strains together with GLP-1 medications, so medication-specific benefit and tolerability remain unknown. Anyone using prescription weight-management medication should discuss supplements with the prescriber managing that treatment.

Disclaimer: Educational information only, not medical advice. Probiotics are not a treatment for obesity or any disease. Talk to a qualified healthcare provider before starting a supplement, especially if you are pregnant, nursing, immunocompromised, or taking medication. These statements have not been evaluated by the Food and Drug Administration.

References

1. Stenman LK, et al. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults: A Randomized Controlled Trial. EBioMedicine. 2016;13:190–200. Full text (PMC)
2. Kadooka Y, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010;64(6):636–643. PubMed
3. Kadooka Y, et al. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr. 2013;110(9):1696–1703. Cambridge Core
4. Sánchez M, et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr. 2014;111(8):1507–1519. Cambridge Core
5. Kim J, et al. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J Med Food. 2018;21(5):454–461. PubMed